Viking Therap

Q2 FY2026 EarningsQ2 FY26 results beat consensus on EPS, reporting a GAAP loss of -$1.10 vs. the -$1.24 expected. As a clinical-stage biopharmaceutical company, revenue remained at $0.0, aligning with expectations. R&D expenses rose to $115.8M as the Phase 3 VANQUISH trials for VK2735 achieved full enrollment. The cash position of $502M remains robust, though the quarterly net loss expanded 95% YoY to $128.0M due to intensified clinical activity.